LU:NYSELufax Holding Ltd Analysis
Data as of 2026-03-17 - not real-time
$2.26
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Technical outlook: Lufax (LU) is trading well below its 20‑day, 50‑day and 200‑day moving averages (2.58, 2.65 and 2.88 respectively) and the MACD is in bearish territory, indicating continued downside pressure. The RSI sits at 32, suggesting the stock is oversold and could see a short‑term bounce, but the 30‑day volatility of ~65% and a beta above 1 point to a highly erratic price profile.
Fundamental backdrop: The company reports negative operating and profit margins, a ROE of –4 % and a heavy debt load (debt‑to‑equity >55). Yet it holds $57.8 bn in cash, yielding a net‑cash position and a forward P/E of 3.9 versus an industry average of 16.5, making the equity appear deeply discounted. Recent material news includes the filing of the FY‑2024 annual report, a CEO resignation effective 31 Mar 2026, and a shareholder‑rights investigation, all of which add short‑term uncertainty.
Fundamental backdrop: The company reports negative operating and profit margins, a ROE of –4 % and a heavy debt load (debt‑to‑equity >55). Yet it holds $57.8 bn in cash, yielding a net‑cash position and a forward P/E of 3.9 versus an industry average of 16.5, making the equity appear deeply discounted. Recent material news includes the filing of the FY‑2024 annual report, a CEO resignation effective 31 Mar 2026, and a shareholder‑rights investigation, all of which add short‑term uncertainty.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Bearish technical indicators and high volatility
- CEO turnover and pending shareholder lawsuit
- Proximity to near‑term support at $2.22
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Substantial cash buffer offsetting high leverage
- Significant valuation discount relative to peers
- Ongoing regulatory scrutiny in China's credit sector
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Potential upside of ~33 % based on DCF and analyst targets
- Low price‑to‑book and price‑to‑sales multiples
- Improving earnings outlook with forward EPS turning positive
Key Metrics & Analysis
Financial Health
Revenue Growth-31.10%
Profit Margin-13.65%
P/E Ratio3.9
ROE-4.09%
ROA2.10%
Debt/Equity55.13
P/B Ratio0.2
Op. Cash Flow$1.8B
Free Cash Flow$19.7B
Industry P/E16.5
Technical Analysis
TrendBearish
RSI32.3
Support$2.22
Resistance$3.21
MA 20$2.58
MA 50$2.65
MA 200$2.88
MACDBearish
VolumeIncreasing
Fear & Greed Index79.45
Valuation
Fair Value$292.15
Target Price$3.00
Upside/Downside32.80%
GradeUndervalued
TypeValue
Risk Assessment
Beta1.11
Volatility64.76%
Sector RiskMedium
Reg. RiskHigh
Geo RiskHigh
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.